The General Hospital of Western Theater Command clinical trials
The General Hospital of Western Theater Command is the lead sponsor of 7 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Early Phase 1. The drugs named most often in its trials are EBV mRNA vaccine and Lusutrombopag. The most-studied condition is B-Cell Acute Lymphoblastic Leukemia, Adult.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by The General Hospital of Western Theater Command
7 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07483385 · ClinicalTrials.gov ↗ · Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders
Drug: Lusutrombopag |
Not applicable | Recruiting | 2026-01 | China |
|
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
NCT06684639 · ClinicalTrials.gov ↗ · Neuroblastoma
|
Early Phase 1 | Recruiting | 2024-12 | China |
|
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
NCT07519187 · ClinicalTrials.gov ↗ · Relapsed or Refractory Plasma Cell Neoplasms
|
Early Phase 1 | Recruiting | 2026-04 | China |
|
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia
NCT06585345 · ClinicalTrials.gov ↗ · Acute-Leukemia
|
Phase 1/2 | Recruiting | 2024-02 | China |
|
EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allo-HSCT
NCT07674199 · ClinicalTrials.gov ↗ · Patients After Hematopoietic Stem Cell Transplantation
Drug: EBV mRNA vaccine |
Early Phase 1 | Not yet open | 2026-06 | China |
|
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
NCT07277504 · ClinicalTrials.gov ↗ · B-Cell Acute Lymphoblastic Leukemia, Adult
|
Early Phase 1 | Not yet open | 2025-12 | China |
|
Allogeneic UCB-derived CAR-T for B-ALL
NCT07256353 · ClinicalTrials.gov ↗ · B-Cell Acute Lymphoblastic Leukemia, Adult
|
Early Phase 1 | Not yet open | 2025-12 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in The General Hospital of Western Theater Command trials
2 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in The General Hospital of Western Theater Command trials
7 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 7 | 4 |
A trial with sites in more than one country appears in each of those registers.
Questions about The General Hospital of Western Theater Command trials
How many clinical trials does The General Hospital of Western Theater Command sponsor?
The General Hospital of Western Theater Command is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are The General Hospital of Western Theater Command trials recruiting?
Yes. 4 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is The General Hospital of Western Theater Command testing?
Its current trials name 2 drugs and biologicals as interventions. The most frequent are EBV mRNA vaccine (1) and Lusutrombopag (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.